Skip to content


The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

Not all products are cleared or available for sale in all Asia Pacific countries.

By clicking on the button "Accepted and Confirmed" you assure that you have taken note of this information and that you are a healthcare professional.

Minimizing your patients’ risks for cardiovascular morbidity and mortality

Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost every other dialysis patient dies from cardiovascular complications1.

Fresenius Medical Care supports nephrologists worldwide in minimizing their patients’ risks for cardiovascular morbidity and mortality.

HighVolumeHDF® therapy as well as innovative membranes like Helixoneplus and modern monitoring features like the Blood Volume Monitor, together with ultrapure dialysis fluid, help minimize CVD risk factors and significantly improve hemodialysis therapy.

Fresenius Medical Care strives continuously to develop and implement innovative therapies and products to improve the cardiovascular prognosis of dialysis patients.

1. Mario Cozzolino et al. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018 Oct; 33(Suppl 3): iii28–iii34

If you would like to be contacted by Fresenius Medical Care, please provide the information requested below (*mandatory fields):